Showing results (391-400 of 523) with videos related to

Sort By:
Pageof 53
Dermatology (Basel, Switzerland)|April 19, 2023
Patient Perspectives on Psoriatic Disease Burden: Results from the Global Psoriasis and Beyond SurveyApril W Armstrong, Barbra Bohannan, Sicily Mburu, et al.
Advances in Therapy|April 7, 2025
Baseline Characteristics and Treatment Patterns of Patients with Atopic Dermatitis Treated with Oral Systemic Therapies: An Interim Analysis of the AD-REAL StudyMatthias Augustin, Esther Serra-Baldrich, Julien Seneschal, et al.
Wound Repair and Regeneration : Official Publication of the Wound Healing Society [And] the European Tissue Repair Society|December 29, 2020
Development and psychometric evaluation of the U.S. English Wound-QoL questionnaire to assess health-related quality of life in people with chronic woundsRachel Sommer, Catharina C von Stülpnagel, Caroline E Fife, et al.
The Journal of Dermatological Treatment|November 27, 2025
Reduction of impairment of sexual activity in patients with genital psoriasis treated with risankizumab: interim results of a real-world studyNesrine Ben-Anaya, Tony Yip, Christina Sorbe, et al.
Acta Dermato-Venereologica|December 22, 2021
Physician-reported Clinical Unmet Needs, Burden and Treatment Patterns of Paediatric Psoriasis Patients: A US and EU Real-world Evidence StudyMarieke M B Seyger, Matthias Augustin, Michael Sticherling, et al.
Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete|August 21, 2021
[Treatment of psoriasis with secukinumab : Practical guidance]Andreas Körber, Matthias Augustin, Frank Behrens, et al.
The British Journal of Dermatology|January 22, 2022
How do dermatologists' personal models inform a patient-centred approach to management: a qualitative study using the example of prescribing a new treatment (Apremilast)Rachael M Hewitt, Chris Bundy, Antonia-Luise Newi, et al.
The British Journal of Dermatology|July 6, 2022
Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1)Andrew Blauvelt, Alexa B Kimball, Matthias Augustin, et al.
Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete|July 9, 2020
[Sucrose octasulfate-evidence in the treatment of chronic wounds]Joachim Dissemond, Matthias Augustin, Michael Dietlein, et al.
Dermatology and Therapy|January 29, 2025
Baricitinib Provides Significant Improvements in Quality of Life and Functioning in Adults with Moderate-to-Severe Atopic Dermatitis with Baseline Body Surface Area ≤ 40% and Severe ItchMatthias Augustin, Maddalena Napolitano, Rosa Izu-Belloso, et al.
Pageof 53